Table 1 Sociodemographic characteristics, overall and by cannabis use status group.

From: Symptom trajectories over time by cannabis use status among patients undergoing cancer treatment

 

Overall

Non-use

Occasional use

Consistent use

p

N = 218

66.97% (n = 146)

12.84% (n = 28)

20.18% (n = 44)

Age, M (SD)

57.51 (13.02)

58.18 (13.24)

59.32 (12.53)

54.11 (12.27)

0.14

Female, % (No.)

71.1 (155)

74.0 (108)

75.0 (21)

59.1 (26)

0.14

Minoritized race, % (No.)

9.6 (21)

8.2 (12)

10.7 (3)

13.6 (6)

0.50

Hispanic, % (No.)

5 (11)

5.5 (8)

3.6 (1)

4.5 (2)

1

Education ≤ HS, % (No.)

83.5 (182)

84.9 (124)

82.1 (23)

79.5 (35)

0.65

Income <$50KB, % (No.)

44.3 (94)

37.1 (52)

50.0 (14)

63.6 (28)

0.01

Employed full/part time, % (No.)

39.0 (85)

29.4 (64)

2.8 (6)

6.9 (15)

0.07

BL cancer stage III/IV, % (No.)

45.0 (98)

43.8 (64)

50.0 (14)

45.5 (20)

0.83

Cancer treatment status, active, % (No.)

82.5 (179)

83.5 (121)

82.1 (23)

79.6 (35)

0.84

Months since diagnosis, M (SD)

25.09 (34.04)

27.57 (37.39)

26.15 (32.97)

16.24 (18.80)

0.06

Insurance status**

 Medicare*, % (No.)

40.4 (88)

41.1 (60)

57.1 (16)

27.3 (12)

0.04

 MedicaidB, % (No.)

12.8 (28)

8.2 (12)

10.7 (3)

29.5 (13)

< 0.01

 Private insurance, % (No.)

53.7 (117)

55.5 (81)

46.4 (13)

52.3 (23)

0.67

 Military insurance, % (No.)

7.3 (16)

8.9 (13)

0.0 (0)

6.8 (3)

0.30

 No health insurance, % (No.)

2.8 (6)

2.7 (4)

0.0 (0)

4.5 (2)

0.68

Smoking status

 Never smokerB, % (No.)

72.9 (159)

82.2 (120)

64.3 (18)

47.7 (21)

< 0.001

 Former smokerB, % (No.)

14.2 (31)

8.9 (13)

17.9 (5)

29.5 (13)

< 0.01

 Current smoker*, % (No.)

12.8 (28)

8.9 (13)

17.9 (5)

22.7 (10)

0.04

 BL MCLA,B,C, % (No.)

18.0 (39)

3.4 (5)

21.4 (6)

65.1 (28)

< 0.001

 PBL MCLA,B,C, % (No.)

4.6 (10)

0.0 (0)

14.3 (4)

13.6 (6)

< 0.001

  1. Income missing n = 6; MCL at BL, months since diagnosis, and treatment status are missing n = 1.
  2. BL Baseline, PBL post-baseline, MCL Medical Cannabis License.
  3. *Overall significant difference by stratum, but post-hoc tests did not show significant differences after Bonferroni correction.
  4. **Some participants had more than one type of insurance.
  5. ANon-use vs. occasional use categories differed significantly.
  6. BNon-use vs. consistent use. categories differed significantly.
  7. COccasional vs. consistent use categories differed significantly.